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Recombinant  subunit  vaccines  in general  are  poor  immunogens  likely  due  to  the  small  size of  pep-
tides  and proteins,  combined  with  the  lack  or reduced  presentation  of  repetitive  motifs  and  missing
complementary  signal(s)  for optimal  triggering  of the  immune  response.  Therefore,  recombinant  sub-
unit  vaccines  require  enhancement  by  vaccine  delivery  vehicles  in  order  to  attain  adequate  protective
immunity.  Particle-based  delivery  platforms,  including  particulate  antigens  and  particulate  adjuvants,article
elivery
djuvant
are  promising  delivery  vehicles  for modifying  the  way  in  which  immunogens  are  presented  to  both  the
innate  and  adaptive  immune  systems.  These  particle  delivery  platforms  can  also  co-deliver  non-speciﬁc
immunostimodulators  as  additional  adjuvants.  This  paper  reviews  efforts  and  advances  of  the  Particle-
based  delivery  platforms  in  development  of vaccines  against  malaria,  a  disease  that  claims  over  600,000
lives  per year,  most  of  them  are  children  under  5  years  of age  in  sub-Sahara  Africa.. Introduction
Compared to inactivated or live-attenuated whole sporozoites
nd whole merozoites, malaria vaccine development strategies
sing recombinant subunits and/or synthetic peptides have the
dvantage of directing the immune responses toward speciﬁc
argets. These strategies, in general, are amenable to large-scale
ontrolled manufacturing processes leading to the production
f a well-characterized antigen with acceptable purity at a low
ost. Multiple malaria vaccine targets, most of which are anti-
ens expressed on the surface of parasites in liver, blood, and
osquito stages, have been evaluated for their ability to induce
rotective immunity [1]. Promising protective immunity was  often
bserved in initial proof-of-concept studies where animals were
mmunized with the soluble recombinant proteins formulated with
reund’s adjuvants. However, the level of protection declined or
as lost in clinical trials when these proteins were formulated
ith adjuvants suitable for human use [2,3]. The development of
TS,S, a recombinant subunit vaccine based on the Plasmodium
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falciparum circumsporozoite protein (PfCSP) present on the sur-
face of infectious sporozoites, has demonstrated the critical roles
of adjuvants and delivery vehicle in order to achieve a signiﬁcant
efﬁcacy. Despite mounting evidence that recombinant PfCSP was
capable of inducing protective immunity against malaria infection,
it was  not until certain modiﬁcations to the formulation were made
that the RTS,S vaccine demonstrated a signiﬁcant level of protec-
tion against clinical malaria. These modiﬁcations include: (i) PfCSP
was fused to and co-expressed with the hepatitis B Surface antigen
(HBsAg) which then self-assembled to form a virus-like particle
(VLP), with multiple copies of PfCSP presented on the particle sur-
face; and (ii) the VLP was  delivered in an oil-in-water emulsion or
a liposomal formulation containing additional immunostimulatory
molecules such as MPL  and QS21 [3,4].
VLPs, stable emulsions, and liposomes belong to a category of
nanoparticle-based delivery platforms that have gained increas-
ing interests in recent years due to their ability to enhance the
immunogenicity of recombinant subunit vaccines (Table 1). A
nano-sized particle displaying high-density repetitive antigens or
epitopes, devoid of invasive pathogenic materials yet permitting
inclusion of desired immunostimulatory molecules, is an ideal
representation that enables incorporation of quality-by-design
concepts during vaccine development. There are multiple beneﬁts
to these platforms. First, a successful immune response, be it
a pathogen or a vaccine, requires the ability of antigens to be
taken up by antigen presenting cells (APCs), processed and pre-
sented to immune effectors. At a size comparable to pathogenic
tp://creativecommons.org/licenses/by/4.0/).
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Table  1
Particle-based delivery platforms.
Type Characteristics* Reference
Particulate antigens Virus-like particles (VLP) Viral capsid protein self-assembled to form a stable core;
exogenous target antigens are displayed repetitively on the surface
by recombinant fusion or chemical conjugation to the viral capsid
protein. A lipid membrane may be present for certain VLPs (e.g.
retrovirus derived VLPs)
[5,64]
Virosomes Lipid-enveloped VLPs without viral capsid core; exogenous target
antigens are displayed repetitively on the envelop surface.
Antigens can be inserted by chemical conjugation to the lipids or
through the natural transmembrane domain present on native
proteins; co-delivery of additional immunostimulants possible
[13]
Self-assembling polypeptide
nanoparticles (SAPN)
Polypeptide core scaffold formed by multiple coiled-coils
oligomerization domains; target antigens are present at the N- and
C-termini of the scaffold polypeptide, and displayed repetitively
on the core surface
[18]
Antigen-carrier conjugates Polypeptides, polysaccharides, or recombinant proteins are
chemically conjugated to a protein carrier, and cross-linked to
form a matrix
[34]
BLPs Micron-sized; peptidoglycan (PGN) matrices derived from food
grade bacteria; target antigens are recombinantly tagged with a
PGN-binding domain and displayed on the matrix surface by
non-covalent interaction with PGN
[8,9]
Particulate Adjuvants Liposomes Lipid bilayer vesicles with an aqueous core; target antigen may be
displayed on vesicle surface, intercalated in lipid bilayer, or
entrapped in aqueous core; co-delivery of additional
immunostimulants
[40,42]
O/W emulsions Nano-to-micron-sized, oil droplets are emulsiﬁed in bulk water
phase; target antigens may  interact with the oil droplets by
hydrophobicity or electrostatic force; co-delivery of additional
immunostimulants
[51,65]
W/O  emulsions Nano-to-micron-sized, water droplets are emulsiﬁed in bulk oil
phase; target antigens are entrapped in the water droplets
[66]
Iscomatrix A cage-like structure formed at interactions between
phospholipids and saponin-cholesterol micelles; target antigens
are entrapped in the void space of the cage
[67]
Biodegradable polymers Nano-to-micron-sized; bio-degradable synthetic polymers such as
poly (lactic-co-glycolic) acid (PLGA); target antigens are entrapped
within the polymer
[61]
Aluminum salts Micron-sized; porous aggregates of ﬁbrous aluminum hydroxide
or plate-like aluminum phosphate; target antigens are adsorbed to
aluminum salts by electrostatic attractive force or trapped in void
paces
[68]
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* The particles are nano-sized unless otherwise indicated.
icroorganisms, the antigen-bearing nanoparticles are more easily
ecognized and efﬁciently taken up by APCs at the site of vaccine
njection [5]. Second, Pattern Recognition Receptors (PRRs) of the
nnate immune system are the ﬁrst line of host defense against a
athogen. PRRs recognize speciﬁc Pathogen-Associated Molecular
atterns (PAMPs) that leads to the induction of a proinﬂammatory
esponse responsible for the induction of both innate and subse-
uently adaptive immunity. Presence of high-density repetitive
pitopes on particle surface facilitates B-cell activation through
ell surface receptor oligomerization and the generation of speciﬁc
ntibodies with higher afﬁnity [6,7]. Third, prolonged and con-
rolled release of target antigens from the particle will result in a
depot” effect favoring the induction of lasting immune responses.
ast but not least, the particle may  allow co-delivery of antigen
nd immunostimulatory adjuvants such as toll-like receptor (TLR)
gonists to the same APC, ensuring a speciﬁc APC activation.
This review aims to summarize efforts and advances in apply-
ng nanoparticle-based delivery platforms to enhance the immune
esponse of malaria vaccines based on recombinant antigens or
ynthetic peptides. The focus is directed toward the works pub-
ished from 2010 and onwards. Though they will not be discussed in
his review, it is worth noting that aluminum salts and Bacterium-
ike Particle (BLP) are also particulate in nature. However, they are
icron-sized, and their modes of action in immune enhancement
iffer from those of nanoparticles. To date, aluminum salts do not
ppear to provide adequate adjuvanticity to recombinant malaria within the aggregates
vaccine candidates. On the other hand, BLPs have shown some
promising immune enhancement that warrant further exploration
[8,9]. RTS,S, a particulate antigen formulated in particulate adju-
vant, is the subject of a separate review article in this issue [200].
2. Particulate antigens
2.1. Virus-like particles
There are two  main types of VLPs: (i) the non-enveloped VLPs
made of viral capsid proteins that self-assemble into stable struc-
tures. The vaccine target antigens can be recombinantly fused to
the viral protein and displayed on the particle surface; and (ii)
enveloped VLPs harboring a lipid membrane with the vaccine target
antigens anchored at the surface. Among enveloped VLPs there are
two categories: those having a core of proteins forming a capsid-
like structure surrounded by a lipid membrane, and those devoid
of a protein core and having only a lipid membrane with the target
antigens embedded, such as the inﬂuenza virosomes. In the latter
case, target antigens could be recombinant proteins or synthetic
peptides that are conjugated to lipid tails for membrane anchoring,
or it could be native proteins with their own  transmembrane and
cytoplasmic domain.
Utilizing recombinant expression in Tobacco plants as a plat-
form technology, Jones et al. constructed an expression vector
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ncoding Pfs25, a P. falciparum ookinete surface protein and a
ransmission blocking vaccine candidate, fused to the coat protein
CP) of Alfalfa mosaic virus [10]. The puriﬁed recombinant prod-
ct composed of the Pfs25-CP fusion protein and two  truncated
P polypeptides, in planta co-assembled to form VLPs 20 nm in
iameter. The requirement of the truncated viral coat protein in the
ssembly process is reminiscent of RTS,S, where assembly of PfCSP-
BsAg VLP also required truncated HBsAg [3]. Interestingly, mice
mmunized with Pfs25-CP VLPs formulated in Alhydrogel® elicited
igh-titer, long-lasting transmission blocking antibodies even with
 single vaccination dose. A Phase 1 trial with Pfs25-CP VLP formu-
ated with Alhydrogel® has been conducted in healthy adults in the
SA though the results are not yet published [101].
Enhancement of antibody responses by VLP was also demon-
trated in study in rhesus monkeys immunized with soluble and
articulate versions of a vaccine based on Plasmodium vivax CSP,
.k.a CSV [11]. Four groups of rhesus monkeys were immunized
ith two doses each of a soluble form of the vaccine (VMP001)
r the particulate version (CSV-S,S). The latter are VLPs that are
ormed by fusing VMP001 to hepatitis B Surface antigen (CVS-S)
nd co-expressing with free HBsAg to form CSV-S,S. While both
accines, formulated with AS01 which consists of MPL, QS21 and
iposomes, induced robust cellular and humoral responses, CSV-
,S generated higher antibody titers, particularly with regard to a
otentially protective B cell epitope.
Another way to present target antigens on the surface of a VLP is
y chemical conjugation of a recombinant antigen to the surface of a
reassembled VLP. A well tested example of this principle is the VLP
ormed from the capsid protein of the bacteriophage Q· The amino
roup of the surface exposed Lysine residues are reacted with a
i-functional chemical cross-linker which is subsequently reacted
ith the target antigen engineered to contain a reactive Cysteine
esidue. The resulting VLP products present repetitive arrays of
he target epitope on the particle surface. This platform has been
valuated extensively in therapeutic vaccines such as ones against
icotine dependence, hypertension, and Alzheimers diseases [12].
he Qb VLP has also been used as a core to present multiple copies
f recombinant Pfs25 on its surface. Immunizing mice with the
fs25-Q VLP, formulated with or without Alhydrogel®, induced
nti-Pfs25 antibody titers higher than that of Pfs25-EPA conju-
ates. The antibodies displayed transmission blocking activity, and
tronger IgG2 and IgG3 titers indicating a Th1 response induced by
fs25-Qb VLP [201].
Virosomes, enveloped VLPs constituted of phospholipids and
iral proteins, may  incorporate the target antigens by coupling
hem to lipid components of the envelope. Although virosomes
an be produced from a variety of enveloped viruses, the inﬂuenza
irus has been the dominant substrate for producing virosome-
ased vaccines [13]. The virosomal delivery platform beneﬁted
rom an extensive human safety proﬁle, as demonstrated over
he last 20 years in adults as well as children, elderlies, and
mmune-compromised populations [14,15]. Early efforts of con-
ugating virosomes with peptides derived from repeat region of
fCSP and an ectodomain of the P. falciparum apical membrane
ntigen-1 (PfAMA1), a micronemal protein involved in merozoite
nvasion led to several clinical trials. When evaluated indi-
idually, both PfCSP-virosome (PEV302T) and PfAMA1-virosome
PEV301T) formulations demonstrated excellent safety, tolerabil-
ty and immunogenicity, though none of the participants were
rotected against blood stage infection in a challenge study [13].
owever, when PEV302T and PEV301T were administered in com-
ination, a reduction in the malaria incidence rate was  observed
n children aged 5–9 years old, indicating the value of a multiva-
ent vaccine approach [16]. The virosome was also used to deliver
MZ2, a recombinant fusion protein consisting of the N-terminal
ortion of the P. falciparum Glutamate Rich Protein (PfGLURP)2015) 7518–7524
and C-terminal fragment of the P. falciparum Merozoite Surface
Protein 3 (PfMSP3). Although the antibody titer elicited by the
unadjuvanted GMZ2-virosome conjugate was  merely comparable
to the titer by GMZ2 formulated with alum [17], the result seemed
encouraging for 2 reasons: (i) In addition to small peptide focusing
on key epitopes (also called mimotopes), the virosome is a versa-
tile platform allowing also the delivery of small-to-large size (∼2 to
100 kDa) recombinant antigens, some in dimeric or trimeric forms;
and (ii) Virosome platform still has the potential to further enhance
immunity if additional and relevant adjuvants are inserted into
the lipid membrane or packaged within the aqueous core of the
virosomes.
2.2. Self-assembling polypeptide nanoparticles (SAPNs)
Self-Assembling Polypeptide Nanoparticles (SAPN) are based
on the alpha-helical coiled-coil oligomerization motifs present in
protein sequences that allow them to self-assemble into well-
deﬁned ordered structures. The basic building block of the SAPN
is a monomeric polypeptide chain containing one pentameric
and one trimeric coiled-coil oligomerization domains. Driven by
these domains, about 60 polypeptide chains self-assemble into an
ordered structure with icosahedral symmetry, exposing both N-
and C terminal ends on the surface [18]. Extending the polypeptide
chain with target epitopes would allow presentation of the target
epitopes in a repetitive array on the particle surface.
To test this novel concept for development of malaria vaccines,
Kaba et al. designed and recombinantly produced a polypeptide
chain based on the pentameric coiled-coil sequence of cartilage
oligomeric matrix protein (COMP), a de novo-designed trimeric
coiled-coil, and a B cell immunodominant repeat epitope of Plas-
modium berghei CSP that assembled into ∼25 nm particles [19].
Immunized mice generated CD4+ T cell-dependent, high-titer,
high-avidity long-lasting antibody responses that were capable of
protecting mice challenged with P. berghei sporozoites. In order to
develop the SAPN platform for human use, the pentameric coiled-
coil forming sequence was switched from the COMP domain to a de
novo designed Tryptophan-zipper to prevent possible cross reac-
tivity [20,21]. Interestingly the replacement of the COMP sequence
resulted in a loss of immunogenicity and protective efﬁcacy in mice,
which was restored by introducing a universal helper T cell epitope
PADRE into the trimeric coiled-coil domain. These second genera-
tion constructs were designed to expose the immunodominant B
cell epitope from the repeat region of P. falciparum CS at the surface
of the SAPNs and also included three P. falciparum CD8+ epitopes
within the scaffold of the nanoparticle. The long-lasting antibodies
elicited by the new SAPNs were capable of protecting mice chal-
lenged with Tg-Pb/PfCSP, a transgenic P. berghei parasite expressing
PfCSP on its sporozoite surface [20]. Using SAPNs that contained
heterologous B cell epitopes and/or lacked the CD8 epitopes, pro-
tection was demonstrated to be mediated via both antibodies and
CD8 T cells. The process to produce these SAPNs is amenable to
cGMP manufacturing [22] and they are currently being developed
further for human testing.
2.3. Antigen-carrier conjugates
Development of chemical conjugate vaccines, in general, is
based on early work using non-immunogenic targets or haptens
chemically conjugated to a “carrier protein”. Active immuniza-
tion with hapten-carriers enabled production of hapten speciﬁc
antibodies due to appropriate communication between T cells
and B cells [23]. These observations supported production of
chemically conjugated polysaccharide vaccines that switch T
cell-independent antigen presentation of polysaccharide moieties
to T cell-dependent antigens for use in licensed vaccines for
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redominately young children against Neisseria meningitides,
aemophilus inﬂuenza type b and Streptococcus pneumoniae [24].
arious carriers are used in these commercial vaccines including
ross reactive material of diphtheria detoxiﬁed toxin bearing an
mino acid substitution, identiﬁed as CRM197; Tetanus toxoid (TT),
nd meningococcal outer membrane protein complex (OMPC) [25].
Encouraging results were obtained by conjugating Pfs25 to
MPC: the conjugation signiﬁcantly enhanced the antibody titers in
ice, rabbits, and non-human primates. Chemical coupling did not
eem to affect functional epitopes, as the correlation between the
onjugate-induced antibody titres and their transmission reducing
ctivities was similar to that induced by soluble Pfs25 formu-
ated with Montanide® ISA51, a water-in-oil formulation. More
nterestingly, the antibody response induced by the conjugate was
ustained for 2 years, and recalled by a booster dose of Pfs25 for-
ulated with an aluminum adjuvant [26]. It was noted that OMPC
iffers from other carriers in that its proteins are present in a liposo-
al  form containing lipids, including lipopolysaccharide, a natural
djuvant. The potential for development of a Pfs25-OMPC chemical
onjugate vaccine is under further investigation.
A well-deﬁned protein carrier, the recombinant Pseudomonas
eruginosa detoxiﬁed toxin, ExoProtein A (rEPA) produced in
scherichia coli, has also demonstrated the capacity of immune
nhancement [27]. Although rEPA is not yet a component of any
icensed vaccine, it appears to be safe in humans including infants
28–31]. Early preclinical studies evaluating the immunogenicity
f chemically conjugated recombinant Pfs25 and Pfs28 to rEPA
ormulated on Alhydrogel® demonstrated an enhanced functional
ntibody response, which was further enhanced by adding CpG
27,32,33]. A pilot-scale production process was developed to man-
facture a Pfs25-EPA conjugate in compliance with current good
anufacturing practices [34], and a Pfs25-EPA/Alhydrogel® formu-
ation was tested in Phase 1 trials in US and Mali adults [102,202].
f particular interest, the Pfs25-EPA chemical conjugate appears
s a nanoparticle in solution with a similar diameter to VLPs of
he RTS,S vaccine [34]. A second Phase 1 trial in US and Mali
dults is in progress testing a second generation of Pfs25-EPA con-
ugate vaccine, using a recombinant Pfs25 protein without any
eterologous amino acids, alone and in combination with a recom-
inant subdomain of a P. falciparum gamete surface protein Pfs230
hemically conjugated to EPA [103,203]. Unfortunately, chemical
onjugation of larger recombinant proteins may  not provide a sim-
lar immunological beneﬁt. For example, chemical conjugation of
wo recombinant proteins larger than 40 kDa to rEPA failed to pro-
ide any signiﬁcant enhancement in immunogenicity when tested
n small animals [35] [204].
Chemical conjugation of the nontoxic cholera toxin B subunit
ith recombinant Pvs25, a Pfs25 ortholog on P. vivax zygote surface,
as been reported to increase the transmission reducing efﬁcacy
gainst P. vivax [36]. Miyata et al. also developed a novel strategy
o increase immune responses by creating genetic fusion proteins
o target speciﬁc APCs. The fusion complex was composed of three
hysically linked molecular entities: (i) A vaccine antigen, (ii) A
ultimeric alpha-helical coiled-coil core, and (iii) An APC-targeting
igand linked to the core via a ﬂexible linker. Immunization of mice
ith the tricomponent complex fused to Pvs25 induced a robust
ntibody response and conferred substantial levels of P. vivax trans-
ission blockade [37].
Epitope repetition within conjugates, in addition to particle
ormation is likely to be another mechanism of immune enhance-
ent. Kubler-Kielb et al. demonstrated that polymerizing Pfs25
y chemical conjugation to itself improved Pfs25 immunogenic-
ty and response longevity in mice [38]. The multimeric Pfs25 core,
n addition to its own merit as a target antigen, was  also used as a
arrier for conjugation with the central repeats of PfCSP. The conju-
ation enhanced immunogenicity of the PfCSP repeats in mice [39],2015) 7518–7524 7521
likely due to the epitope repetition and the particulate nature of
the conjugates.
3. Particulate adjuvants
3.1. Liposomes
Liposomes are self-assembling spherical vesicles composed of
a phospholipid bilayer enclosing an aqueous core. Liposomes can
also be made as multilamellar in which multiple concentric lipid
bilayers are separated by aqueous layers. Liposomes have versatile
ways to deliver target antigens and additional immunomodulators
as adjuvants. Depending upon chemical and biochemical proper-
ties, water-soluble target antigens can be entrapped within the
aqueous phase, and lipophilic molecules can be intercalated within
the lipid bilayer. Antigens and adjuvants can also be attached to
the surface of liposomes by adsorption, covalent conjugation, and
electrostatic interactions. Liposomes have been broadly applied to
enhance T and B cell responses to subunit vaccines candidates,
including several being evaluated in humans [4,40–42].
The most advanced application of the liposomal delivery sys-
tem in malaria vaccine development is AS01, an Adjuvant System
comprised of liposome, QS21, and MPL, a TLR4 agonist. In comple-
tion of a multi-center Phase 3 trial of RTS,S/AS01 involving >15,000
children including 6000 infants in malaria endemic regions, the
adjuvant has an extensive safety proﬁle [200]. In addition to RTS,S,
several recombinant malaria antigens formulated with AS01 have
been evaluated in humans. These include LSA-NRC, a recombi-
nant protein comprised of N-and C-terminal regions and two of
the central repeats of P. falciparum Liver Stage Antigen 1 and a
candidate vaccine to block merozoite egress from hepatocytes, in
a Phase 1 trial in US adults followed by a Phase 2a sporozoite
challenge [43]; AMA1, a recombinant ectodomain of P. falciparum
merozoite apical membrane antigen 1, in a Phase 1 trial in US
adults followed by a Phase 2a sporozoite challenge [44]; and
MSP142, the 42 kDa N-terminal region of P. falciparum merozoite
surface protein 1, in a Phase 1 trial in US adults followed by a
second Phase 1 trial in Kanyan adults [45]. All formulations demon-
strated reassuring safety proﬁles. Despite the fact that none of
these formulations showed any protection in challenge studies
(for PfLSA-NRC and PfAMA1) or in growth inhibition assay (for
PfMSP142), all have elicited high titers of speciﬁc antibodies. In
addition, PfLSA-NRC/AS01 formulation induced higher CD4+ T cell
response than did PfLSA-NRC formulated with AS02, another Adju-
vant System and an oil-in-water emulsion also containing MPL  and
QS21 (see Section 3.2), indicating the role of liposomal formulation
in induction of cellular responses [43]. However, no signiﬁcant dif-
ference was found in CD4 responses induced by PfAMA1/AS01 or
by PfAMA1/AS02 [44].
The PfAMA/AS01 and PfAMA1/AS02 were also evaluated in UK
healthy adults, followed by a challenge with blood-stage parasites
[104]. Also being evaluated in human trials were PfCelTOS/AS01
[105] and PvCSP/AS01 [106], two  vaccine candidates to block
sporozoite invasion of hepatocytes by P. falciparum and P. vivax
parasites, respectively. In both studies the participants receiving
the full intended dose were challenged with falciparum or vivax
sporozoites. Anticipated analysis will shed light whether protec-
tive efﬁcacies, if any, are associated with B cell or T cell responses,
and the role of the adjuvant in these responses.
GLA-LSQ is a novel liposomal adjuvant consisting of liposome,
QS21 and Glucopyranosyl Lipid A (GLA). Since GLA is a known TLR4
agonist [46], GLA-LSQ is expected to have similar adjuvanticity
as AS01. With a recombinant full-length Pf CSP produced in Pseu-
domonas ﬂuorescens expression platform, NOE et al. evaluated the
solubilized rPfCSP in various delivery systems including GLA-LSQ,
GLA in stable emulsion (GLA-SE), and aluminum salts, with the
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ntention to select one for human use. Whereas the GLA-LSQ and
LA-SE formulations were comparable in antibody induction, in
unctional assays including in vitro inhibition of sporozoite invasion
nd in vivo protection against Tg-Pb/PfCSP sporozoite challenge,
PfCSP/GLA-LSQ formulation was a clear winner in induction of
ellular and lasting antibody responses. Partial protection against
porozoite challenge was observed, and it would be interesting
o know whether the protected animals had higher humoral and
ellular responses [47].
While it is unclear how liposomes in AS01 and GLA-LSQ interact
ith the target antigens, the cationic liposomal adjuvants clearly
ttract target antigens with opposite charges through electrostatic
nteraction. One of these is CAF01, a novel liposomal adjuvant
omposed of cationic lipid vesicles stabilized with a glycolipid
mmunostimulant TDB, a synthetic analogue of mycobacterial cell
all. A CAF01 formulated vaccine candidate against tuberculosis
as shown to be safe and tolerable in humans, and induced strong
asting T-cell responses. However, there was no detectable antibody
esponses in humans, in contrast to observation in preclinical ani-
al  studies [42]. CAF01 has also been used to formulate PyMSP119
48], a recombinant protein based on the 19 kDa C-terminal region
f Plasmodium yoelii MSP1, and DBL4-ID4, a recombinant subunit
f P. falciparum VAR2CSA and a vaccine candidate to protect women
gainst placental malaria [49]. PyMSP119/CAF01 induced signiﬁ-
antly higher IgG1 and IgG2 antibodies in mice than did the alum
ormulation, and conferred a stronger partial protection in mice
rom a blood stage parasite challenge. In the DBL4-ID4/CAF01
tudy, the DBL4-ID4 was also formulated with 2 other adju-
ants: Alhydrogel and Montanide ISA720, a water-in-oil emulsion.
lthough antibody titers induced by all 3 formulations were similar,
he DBL4-ID4/CAF01 induced IgGs displayed a stronger inhibition
f infected erythrocytes binding to chondroitin sulphate proteogly-
ans, and a stronger binding to the target antigen DBL4-ID4.
Interbilayer-crosslinked multilamellar vesicle (ICMV) is another
ype of liposomal delivery system that shows promise. Moon
t al. reported enhanced antigen-speciﬁc humoral responses when
CMVs were used to co-deliver a TLR4 agonist along with PvCSP
hat was either entrapped within the vesicle or entrapped as well
s displayed on the surface of the vesicles ICMV [50]. The result-
ng ∼180 nm particles elicited antibodies that were 9-fold higher
n the formulation with entrapped and surface-displayed PvCSP
ompared to the group which did not have antigen on the sur-
ace. This vaccine delivery method allowed dose-sparing, generated
 more balanced Th1/Th2 response with high avidity long-lasting
ntibodies. The response correlated with the induction of Tfh cells in
erminal centers that formed adjacent to the vaccination site. These
bservations seem consistent with the mechanisms of immune
nhancement by a particulate delivery system.
.2. Stable emulsion
Emulsion-based nanoparticle adjuvants include oil-in-water
O/W) emulsions that interact with target antigens mainly by
ydrophobic or electrostatic forces, and water-in-oil (W/O) emul-
ions that entrap target antigens in water droplets. They have been
idely used in vaccine development, and the O/W emulsion MF59
nd AS03, and W/O  emulsion Montanide® ISA51 are components
f several licensed vaccines [51].
Following unsatisfactory outcomes in animal studies with MF59
djuvanted malaria antigens including P. falciparum AMA1, MPS1,
ERA, Pfs25, and P. vivax Duffy-binding protein, no further clinical
evelopment was  justiﬁed with the adjuvant [52]. Despite superb
mmune-enhancement offered by Montanide® ISA51 and a sim-
lar W/O  emulsion Montanide® ISA720, the adjuvants ceased to
e the choice for clinical development due to high rate of local
eactogenicity and unexpected systemic reactions in Phase 1 trials2015) 7518–7524
[53,54]. On the other hand, AS02, an O/W emulsion with additional
immunostimulants MPL  and QS21, has been shown in clinical trials
to enhance immune responses of multiple malaria antigens includ-
ing P. falciparum AMA1, MSP1 and LSA1, though the adjuvant did
not increase their protective efﬁcacy [43,44]. Although AS02 was
the initial adjuvant that delivered RTS,S with proven clinical efﬁ-
cacy, it was outperformed by RTS,S/AS01 formulation for induction
of humoral and cellular immunity, and protective efﬁcacy [4,55].
GLA-SE, an O/W emulsion containing TLR4 agonist, was
expected to have similar adjuvanticity as AS01 due to their simi-
lar composition except for lacking QS21 in GLA-SE. Indeed, GLA-SE
has a demonstrated capacity to elicit strong Th1 type immune
responses. PbCSP and PfCelTOS formulated with GLA-SE induced
higher level of IgG2 antibodies and more INFγ-producing cells in
mice [56,57]. GLA-SE also has a broad safety proﬁle in humans:
It has been injected in hundreds of humans in multiple Phase 1
trials evaluating vaccine candidates against various diseases. The
completed or currently on-going Phase 1 trials with GLA-SE formu-
lated recombinant malaria antigens include PfCelTOS, PfAMA1, and
PfP27A, a synthetic polypeptide corresponding to the unstructured
domain of P. falciparum Trophozoite exported protein 1 (Tex1)
[107]. While results of these trials are not yet published, the attempt
has been made to further increase the immune enhancing capacity
of GLA-SE by inclusion of additional TLR7/8 agonists, such as R848.
Unfortunately PvSCP formulated with GLA/R848-SE induced lower
humoral and cellular responses in mice [58].
3.3. Others
Several other particulate delivery systems, including ISCOMs
and biodegradable polymers, caught interest of malaria vaccine
developers.
ISCOMs are cage-like particles composed of phospholipids,
saponin-cholesterol micelles and the antigens incorporated into
particles through hydrophobic interaction, which requires a
hydrophobic tag if the target antigen is hydrophilic [59]. Subse-
quently, by using different lipids, Isomatrix® became a versatile
adjuvant system that can entrap any type of target antigens, deliver
the target antigens to APCs, and enhance both B cell and T cell
responses in multiple species. Isomatrix® has been applied to over
one thousand volunteers in Phase 1 and Phase 2 trials evaluat-
ing prophylactic and therapeutic vaccines, and was  shown to be
well tolerated. Regarding malaria antigens, Przysiecki et al. evalu-
ated immunogenicity of (NANP)6-OMPC/MAA, an alum adsorbed,
OMPC-conjugated peptide corresponding to the central repeats of
PfCSP, with and without Isomatrix®. In in-bred mice, addition of
Isomatrix® to the alum formulation did not have much effect on
antibody titer, while in rhesus monkeys, addition of Isomatrix® in
formulation induced a long-lived high-level anti-repeat antibodies
compared to the animals immunized with the formulation with-
out Isomatrix® [60]. The observations prompted cautions of using
alum-formulation as a bench marker for adjuvant selection in mice,
as the species and the adjuvant is widely used in initial proof-of-
concept studies.
Biocompatible and biodegradable polymeric nanoparticles may
represent a promising new technology for improved immune
responses [61]. Their ability to sustain and control the release of
the entrapped antigens and their delivery to APCs raised hope for
eliciting long-lasting immune responses. Among a wide variety of
synthetic polymers used to prepare nanoparticles, poly (lactic-co-
glycolic) acid (PLGA) has been evaluated extensively and is already
in several FDA-approved therapeutic delivery devices. By emul-
sifying PLGA and maleimide-activated lipids, Moon et al. created
new PLGA particles enveloped with a lipid bilayer, which allowed
covalent conjugation of thiolated PvCSP on the particle surface [62].
The resulting PvCSP-NP elicited durable antibody with signiﬁcantly
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igher titers and more balanced Th1/Th2 responses, compared to
he PvCSP monomer. Antibody titers raised by PvCSP-NP were able
o agglutinate P. vivax sporozoites, and exhibited higher avidity
nd afﬁnity toward the recombinant protein. Using a derivative
f PLGA, Dinglasan et al. prepared a nano-to-micron-sized parti-
le incorporated with recombinant AnAPN1, an Anopheles gambiae
minopeptidase in mosquito midgut and a TBV candidate [63].
mmunization of the An-APN1 loaded particle induced functional
ntibodies, as measured by direct feeding of mosquitoes on immu-
ized mice challenged with P. berghei, even 6 months after a single
ose of vaccination.
. Reﬂection and conclusion
Since a strong safety proﬁle in humans is paramount for devel-
pment of prophylactic vaccines, a rather conservative approach
as been taken in adjuvant/delivery selection for recombinant
ubunit-based malaria vaccine candidates. Nearly all clinical trials
ith recombinant malaria antigens started with aluminum salts as
he adjuvant. Now it has become a consensus that recombinant
ubunit vaccines are unlikely to achieve desired protective efﬁ-
acy without an appropriate delivery vehicle that includes not only
djuvant but also a proper antigen presentation format. Particu-
ate delivery of vaccine antigens is advantageous as it can simulate
 pathogen-mimicry by presenting the proteins as larger moi-
ties, allowing more efﬁcient uptake by APCs, stimulating innate
mmune responses through Pattern Recognition Receptors (PRRs),
nd providing depot effect for lasting responses. The licensure
f particle-based vaccines such as HPVs and the accumulation of
afety data in other vaccines in clinical trials has raised the hope
f applying such delivery systems in malaria vaccine development
ithout compromising the safety precaution.
Selection of a suitable delivery platform for a particular malaria
ntigen has been and will likely remain to be empirical. There are
till technical hurdles in optimizing the delivery platforms, par-
icularly with regard to particulate antigens such as VLPs, SAPNs,
nd antigen-carrier conjugates. There seems to be a size and den-
ity limit to the target antigens to be displayed on the particle
urface. To remedy this we need a clear understanding as well as
ools for characterization of the functional epitopes or subdomains
ithin the target antigen, and their native conformation. The pro-
esses and conditions to preserve the native conformation during
he synthetic or recombinant production of the target epitope or
ntigen have to be empirically determined. Other needs that have
o be empirically determined are the processes and conditions to
ncrease the antigen to core/carrier loading ratios. Finally during
election of the delivery platforms, the immune status of the tar-
et population needs to be considered. New born babies and young
nfants may  have different adjuvant requirement as older children
nd adults. Vaccine must be “tailored” according to the immune
tatus of subjects to be vaccinated.
While animal models are always used in initial proof-of-concept
tudies, the deﬁnitive evaluation of a delivery platform has to be
rials conducted humans. It is an exciting time as multiple clini-
al trials have been conducted or are on-going to evaluate several
article-based delivery of subunit malaria antigens. Outcomes of
hese trials will not only help the selection of safe and potent deliv-
ry vehicles, but will also shed light on whether and/or how animal
odels predict the immune response and the protective efﬁcacy in
umans.
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